News and innovation - April 29, 2024
EU Directive 2022/431: What’s in it for healthcare workers?
EU Directive 2022/431 in a nutshell European Union (EU) Directive 2022/431, also known as the Carcinogens, Mutagens and Reprotoxic Substances…
EU Directive 2022/431: What’s in it for healthcare workers?
EU Directive 2022/431 in a nutshell European Union (EU) Directive 2022/431, also known as the Carcinogens, Mutagens and Reprotoxic Substances…
Earth Day 2024: Our planet prefers TIVA anaesthesia—do you?
Healthcare's climate footprint is equivalent to 4.4% of global net emissions; this means that if the health sector were a…
“Complications of IV catheter therapy are simply the result of one complex and highly variable mechanical system—IV catheter equipment design,...
Reducing infection with catheter care bundles
Catheter-related bloodstream infections (CRBSIs) are a serious threat to patients with a vascular access device, yet many are preventable using…
BD IV News 2.0: building an IV therapy community
Your source of information on IV therapy just got a whole lot better. Following feedback from readers, BD IV News…
Join us at the 8th World Congress on Vascular Access (WoCoVA). We’re bringing together a world-class cast of vascular access…
Device and drug shortages in Europe persist, new survey shows
Countries across the globe face a wide range of challenges in accessing necessary health products, such as shortages and stockouts.1…
Scientific evidence on VATs: Is there enough? Is it robust?
There is much scientific evidence available on the efficacy of vascular access teams (VATs) in managing costs, preventing intravenous (IV)…
Fast fact
“I think that the biggest issue in our service is choosing which [vascular access device (VAD)] for which patients,” Professor Caren Randon, MD, PhD